A. Nonsteroid anti-inflammatory drugs B. Angiotensin receptor blockers C. Loop diuretics D. Calcineurin inhibitors

A. Sodium zirconium cyclosilicate may allow patients to remain on renin-angiotensin-aldosterone system-inhibiting therapy. B. Sodium zirconium cyclosilicate has only been studied for chronic use in treating patients with hyperkalemia. C. Sodium zirconium cyclosilicate has only been studied primarily in patients with normal kidney function. D. No cases of hypokalemia have occurred in clinical studies in the sodium zirconium cyclosilicate treatment arm.

A. Treating JH with albuterol B. Treating JH with insulin and dextrose C. Treating JH with Sodium chloride D. Starting JH on dialysis

A. Patiromer does not have any significant drug-drug interactions. B. Patiromer works by shifting potassium intracellularly. C. Patiromer is not approved for the acute treatment of patients with hyperkalemia. D. In clinical studies, the most common adverse event was hypokalemia.

A. It shifts potassium from the extracellular space to the intracellular space. B. It decreases the resting potential of the myocardial cells. C. It is a selective cation exchanger that binds potassium in exchange for hydrogen and sodium ions. D. It inhibits renal tubular reabsorption of sodium and chloride.